organization · Reporting owner

Sumitomo Pharma Co., Ltd.

Disclosed activity across 3 companies

Tapewire entity: 111915
SEC CIK: 0001446601

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Urovant Sciences Ltd.UROV · Entity 140739	See Footnote (1)	February 19, 2020	February 21, 2020

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Urovant Sciences Ltd.

Report date February 19, 2020 · Filed February 21, 2020

Jointly reported with Sumitomo Chemical Co., Ltd., Sumitovant Biopharma Ltd.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	22,963,263	Last balance in matching sequence After 2020-02-19 transaction · row 3 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 3 source rows Row 1 · 2020-02-19 · Purchase · Acquired 12,873 · Balance 22,872,886 F1: Sumitovant Biopharma Ltd. ("Sumitovant") directly owns 22,963,263 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Row 2 · 2020-02-19 · Purchase · Acquired 15,165 · Balance 22,888,051 F1: Sumitovant Biopharma Ltd. ("Sumitovant") directly owns 22,963,263 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Row 3 · 2020-02-19 · Purchase · Acquired 75,212 · Balance 22,963,263 F1: Sumitovant Biopharma Ltd. ("Sumitovant") directly owns 22,963,263 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Sumitovant Biopharma Ltd. ("Sumitovant") directly owns 22,963,263 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Myovant Sciences Ltd.

Report date March 10, 2023 · Filed March 10, 2023

Jointly reported with Sumitomo Chemical Co., Ltd., Sumitovant Biopharma Ltd.

Section 16 reporting ended · disclosed 2023-03-10. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common SharesSEC Table I · non-derivative	IndirectSee Footnote	45,798,176	Reported balance After 2023-03-10 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2023-03-10 · Purchase · Acquired 51,599,200 · Balance 45,798,176 F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of Myovant Sciences Ltd. (the "Issuer") not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. F2: (Continued from footnote 1) Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). At the effective time of the Merger (the "Effective Time"), each common share of the Issuer outstanding immediately prior to the Effective Time (other than certain excluded shares) automatically converted into the right to receive $27.00 in cash, without interest and less any applicable withholding taxes. F3: Sumitovant is a wholly-owned subsidiary of Sumitomo Pharma Co., Ltd. ("Sumitomo Pharma"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Pharma and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Pharma and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of Myovant Sciences Ltd. (the "Issuer") not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto.

F2: (Continued from footnote 1) Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). At the effective time of the Merger (the "Effective Time"), each common share of the Issuer outstanding immediately prior to the Effective Time (other than certain excluded shares) automatically converted into the right to receive $27.00 in cash, without interest and less any applicable withholding taxes.

F3: Sumitovant is a wholly-owned subsidiary of Sumitomo Pharma Co., Ltd. ("Sumitomo Pharma"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Pharma and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Pharma and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein.

Roivant Sciences Ltd.

Report date June 22, 2023 · Filed June 26, 2023

Jointly reported with Sumitomo Chemical Co., Ltd.

Section 16 reporting ended · disclosed 2023-06-26. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common SharesSEC Table I · non-derivative	IndirectSee footnote	71,251,083	Reported balance After 2023-06-22 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2023-06-22 · Sale · Disposed 15,116,277 · Balance 71,251,083 F1: The sale reported on this Form 4 was effected pursuant to a privately negotiated transaction between Sumitomo Pharma Co., Ltd. (formerly Sumitomo Dainippon Pharma Co., Ltd.) ("Sumitomo Pharma") and four purchasers. In connection with the transaction, Sumitomo Pharma entered into a customary lock-up agreement with Roivant Sciences Ltd. ("Roivant") covering the common shares that continue to be beneficially owned by Sumitomo Pharma following the transaction, which lock-up agreement is effective through February 29, 2024.The buyers also entered into customary lock-up agreements with Roivant covering the common shares acquired in the transaction, which lock-up agreements are effective through February 29, 2024. F2: Sumitomo Pharma directly owns 71,251,083 Common Shares. Sumitomo Pharma is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo"). Sumitomo may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitomo Pharma owns. Sumitomo disclaims beneficial ownership of such reported securities except to the extent of its pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The sale reported on this Form 4 was effected pursuant to a privately negotiated transaction between Sumitomo Pharma Co., Ltd. (formerly Sumitomo Dainippon Pharma Co., Ltd.) ("Sumitomo Pharma") and four purchasers. In connection with the transaction, Sumitomo Pharma entered into a customary lock-up agreement with Roivant Sciences Ltd. ("Roivant") covering the common shares that continue to be beneficially owned by Sumitomo Pharma following the transaction, which lock-up agreement is effective through February 29, 2024.The buyers also entered into customary lock-up agreements with Roivant covering the common shares acquired in the transaction, which lock-up agreements are effective through February 29, 2024.

F2: Sumitomo Pharma directly owns 71,251,083 Common Shares. Sumitomo Pharma is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo"). Sumitomo may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitomo Pharma owns. Sumitomo disclaims beneficial ownership of such reported securities except to the extent of its pecuniary interest therein.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
May 13, 2020 Filed May 15, 2020 19:28 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	PurchaseCommon Stock	41,331	$12.38	$511,640.58	Disclosure SEC source: 0000899243-20-013205 · doc4.xml · nonDerivative · entry 1 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 48,418,472 F1 · shares: This acquisition of a total of 41,331 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020 (the "10b5-1 Trading Plan"). F2 · price: The price reported in column 4 is the average stock price. F3 · ownership.nature: Sumitovant Biopharma Ltd. ("Sumitovant") directly owns 48,418,472 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document
May 12, 2020 Filed May 13, 2020 22:50 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	PurchaseCommon Stock	24,448	$13.51	$330,404.94	Disclosure SEC source: 0000899243-20-013027 · doc4.xml · nonDerivative · entry 2 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 48,377,141 F4 · shares: This acquisition of a total of 24,448 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan. F2 · price: The price reported in column 4 is the average stock price. F5 · ownership.nature: Sumitovant directly owns 48,377,141 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document
May 11, 2020 Filed May 13, 2020 22:50 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	PurchaseCommon Stock	35,000	$12.78	$447,384.00	Disclosure SEC source: 0000899243-20-013027 · doc4.xml · nonDerivative · entry 1 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 48,352,693 F1 · shares: This acquisition of a total of 35,000 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020 (the "10b5-1 Trading Plan"). F2 · price: The price reported in column 4 is the average stock price. F3 · ownership.nature: Sumitovant Biopharma Ltd. ("Sumitovant") directly owns 48,352,693 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document
May 08, 2020 Filed May 11, 2020 20:01 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	PurchaseCommon Stock	35,000	$12.83	$449,074.50	Disclosure SEC source: 0000899243-20-012570 · doc4.xml · nonDerivative · entry 2 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 48,317,693 F4 · shares: This acquisition of a total of 35,000 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan. F2 · price: The price reported in column 4 is the average stock price. F5 · ownership.nature: Sumitovant directly owns 48,317,693 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document
May 07, 2020 Filed May 11, 2020 20:01 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	PurchaseCommon Stock	35,000	$12.63	$442,137.50	Disclosure SEC source: 0000899243-20-012570 · doc4.xml · nonDerivative · entry 1 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 48,282,693 F1 · shares: This acquisition of a total of 35,000 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020 (the "10b5-1 Trading Plan"). F2 · price: The price reported in column 4 is the average stock price. F3 · ownership.nature: Sumitovant Biopharma Ltd. ("Sumitovant") directly owns 48,282,693 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document
May 06, 2020 Filed May 11, 2020 20:07 UTC Amendment	Myovant Sciences Ltd. MYOV · Entity 115677	PurchaseCommon Stock	50,000	$12.24	$612,075.00	Disclosure SEC source: 0000899243-20-012574 · doc4a.xml · nonDerivative · entry 1 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 48,247,693 F1 · date: On May 7, 2020, the Reporting Persons filed a Form 4 disclosing the acquisition of 50,000 shares of Common Stock at an average stock price of $11.6893 (the "First Acquisition") and 50,000 shares of Common Stock at an average stock price of $12.2415 (the "Second Acquisition"). The transaction date reported in Box 2 for both the First Acquisition and the Second Acquisition was May 5, 2020. The transaction date for the Second Acquisition was incorrectly reported and should have been reported as May 6, 2020. F2 · shares: This acquisition of a total of 50,000 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020. F3 · price: The price reported in column 4 is the average stock price. F4 · ownership.nature: Sumitovant Biopharma Ltd. ("Sumitovant") directly owns 48,247,693 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document
May 05, 2020 Filed May 7, 2020 13:26 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	PurchaseCommon Stock	50,000	$12.24	$612,075.00	Disclosure SEC source: 0000899243-20-012209 · doc4.xml · nonDerivative · entry 2 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 48,247,693 F4 · shares: This acquisition of a total of 50,000 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan. F2 · price: The price reported in column 4 is the average stock price. F5 · ownership.nature: Sumitovant directly owns 48,247,693 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document
May 05, 2020 Filed May 7, 2020 13:26 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	PurchaseCommon Stock	50,000	$11.69	$584,465.00	Disclosure SEC source: 0000899243-20-012209 · doc4.xml · nonDerivative · entry 1 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 48,197,693 F1 · shares: This acquisition of a total of 50,000 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020 (the "10b5-1 Trading Plan"). F2 · price: The price reported in column 4 is the average stock price. F3 · ownership.nature: Sumitovant Biopharma Ltd. ("Sumitovant") directly owns 48,197,693 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document
May 04, 2020 Filed May 5, 2020 19:40 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	PurchaseCommon Stock	50,000	$11.50	$574,870.00	Disclosure SEC source: 0000899243-20-012040 · doc4.xml · nonDerivative · entry 2 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 48,147,693 F4 · shares: This acquisition of a total of 50,000 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan. F2 · price: The price reported in column 4 is the average stock price. F5 · ownership.nature: Sumitovant directly owns 48,147,693 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document
May 01, 2020 Filed May 5, 2020 19:40 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	PurchaseCommon Stock	50,000	$11.38	$569,180.00	Disclosure SEC source: 0000899243-20-012040 · doc4.xml · nonDerivative · entry 1 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 48,097,693 F1 · shares: This acquisition of a total of 50,000 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020 (the "10b5-1 Trading Plan"). F2 · price: The price reported in column 4 is the average stock price. F3 · ownership.nature: Sumitovant Biopharma Ltd. ("Sumitovant") directly owns 48,097,693 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document
April 30, 2020 Filed May 1, 2020 21:35 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	PurchaseCommon Stock	50,000	$12.08	$603,825.00	Disclosure SEC source: 0000899243-20-011728 · doc4.xml · nonDerivative · entry 2 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 48,047,693 F4 · shares: This acquisition of a total of 50,000 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan. F2 · price: The price reported in column 4 is the average stock price. F5 · ownership.nature: Sumitovant directly owns 48,047,693 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document
April 29, 2020 Filed May 1, 2020 21:35 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	PurchaseCommon Stock	50,000	$11.92	$595,895.00	Disclosure SEC source: 0000899243-20-011728 · doc4.xml · nonDerivative · entry 1 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 47,997,693 F1 · shares: This acquisition of a total of 50,000 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020 (the "10b5-1 Trading Plan"). F2 · price: The price reported in column 4 is the average stock price. F3 · ownership.nature: Sumitovant Biopharma Ltd. ("Sumitovant") directly owns 47,997,693 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document
April 28, 2020 Filed Apr 29, 2020 17:38 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	PurchaseCommon Stock	50,000	$12.05	$602,720.00	Disclosure SEC source: 0000899243-20-011506 · doc4.xml · nonDerivative · entry 2 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 47,947,693 F4 · shares: This acquisition of a total of 50,000 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan. F2 · price: The price reported in column 4 is the average stock price. F5 · ownership.nature: Sumitovant directly owns 47,947,693 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document
April 27, 2020 Filed Apr 29, 2020 17:38 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	PurchaseCommon Stock	40,503	$12.18	$493,302.24	Disclosure SEC source: 0000899243-20-011506 · doc4.xml · nonDerivative · entry 1 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 47,897,693 F1 · shares: This acquisition of a total of 40,503 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020 (the "10b5-1 Trading Plan"). F2 · price: The price reported in column 4 is the average stock price. F3 · ownership.nature: Sumitovant Biopharma Ltd. ("Sumitovant") directly owns 47,897,693 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document
April 24, 2020 Filed Apr 27, 2020 15:30 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	PurchaseCommon Stock	43,086	$12.15	$523,344.10	Disclosure SEC source: 0000899243-20-011334 · doc4.xml · nonDerivative · entry 2 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 47,857,190 F4 · shares: This acquisition of a total of 43,086 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan. F2 · price: The price reported in column 4 is the average stock price. F5 · ownership.nature: Sumitovant directly owns 47,857,190 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document
April 23, 2020 Filed Apr 27, 2020 15:30 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	PurchaseCommon Stock	35,000	$12.35	$432,103.00	Disclosure SEC source: 0000899243-20-011334 · doc4.xml · nonDerivative · entry 1 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 47,814,104 F1 · shares: This acquisition of a total of 35,000 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020 (the "10b5-1 Trading Plan"). F2 · price: The price reported in column 4 is the average stock price. F3 · ownership.nature: Sumitovant Biopharma Ltd. ("Sumitovant") directly owns 47,814,104 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document
April 22, 2020 Filed Apr 23, 2020 18:21 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	PurchaseCommon Stock	50,000	$11.93	$596,730.00	Disclosure SEC source: 0000899243-20-011209 · doc4.xml · nonDerivative · entry 2 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 47,779,104 F4 · shares: This acquisition of a total of 50,000 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan. F2 · price: The price reported in column 4 is the average stock price. F5 · ownership.nature: Sumitovant directly owns 47,779,104 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document
April 21, 2020 Filed Apr 23, 2020 18:21 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	PurchaseCommon Stock	50,200	$11.58	$581,140.30	Disclosure SEC source: 0000899243-20-011209 · doc4.xml · nonDerivative · entry 1 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 47,729,104 F1 · shares: This acquisition of a total of 50,200 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020 (the "10b5-1 Trading Plan"). F2 · price: The price reported in column 4 is the average stock price. F3 · ownership.nature: Sumitovant Biopharma Ltd. ("Sumitovant") directly owns 47,729,104 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document
April 20, 2020 Filed Apr 21, 2020 20:01 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	PurchaseCommon Stock	50,300	$11.82	$594,425.28	Disclosure SEC source: 0000899243-20-011041 · doc4.xml · nonDerivative · entry 2 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 47,678,904 F4 · shares: This acquisition of a total of 50,300 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan. F2 · price: The price reported in column 4 is the average stock price. F5 · ownership.nature: Sumitovant directly owns 47,678,904 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document
April 17, 2020 Filed Apr 21, 2020 20:01 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	PurchaseCommon Stock	70,000	$10.76	$753,536.00	Disclosure SEC source: 0000899243-20-011041 · doc4.xml · nonDerivative · entry 1 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 47,628,604 F1 · shares: This acquisition of a total of 70,000 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020 (the "10b5-1 Trading Plan"). F2 · price: The price reported in column 4 is the average stock price. F3 · ownership.nature: Sumitovant Biopharma Ltd. ("Sumitovant") directly owns 47,628,604 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document
April 16, 2020 Filed Apr 17, 2020 16:38 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	PurchaseCommon Stock	70,000	$10.64	$744,674.00	Disclosure SEC source: 0000899243-20-010899 · doc4.xml · nonDerivative · entry 2 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 47,558,604 F4 · shares: This acquisition of a total of 70,000 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan. F2 · price: The price reported in column 4 is the average stock price. F5 · ownership.nature: Sumitovant directly owns 47,558,604 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document
April 15, 2020 Filed Apr 17, 2020 16:38 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	PurchaseCommon Stock	70,000	$10.48	$733,698.00	Disclosure SEC source: 0000899243-20-010899 · doc4.xml · nonDerivative · entry 1 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 47,488,604 F1 · shares: This acquisition of a total of 70,000 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020 (the "10b5-1 Trading Plan"). F2 · price: The price reported in column 4 is the average stock price. F3 · ownership.nature: Sumitovant Biopharma Ltd. ("Sumitovant") directly owns 47,488,604 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document
April 14, 2020 Filed Apr 15, 2020 23:22 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	PurchaseCommon Stock	70,000	$11.00	$770,105.00	Disclosure SEC source: 0000899243-20-010804 · doc4.xml · nonDerivative · entry 2 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 47,418,604 F4 · shares: This acquisition of a total of 70,000 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan. F2 · price: The price reported in column 4 is the average stock price. F5 · ownership.nature: Sumitovant directly owns 47,418,604 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document
April 13, 2020 Filed Apr 15, 2020 23:22 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	PurchaseCommon Stock	70,000	$9.81	$686,546.00	Disclosure SEC source: 0000899243-20-010804 · doc4.xml · nonDerivative · entry 1 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 47,348,604 F1 · shares: This acquisition of a total of 70,000 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020 (the "10b5-1 Trading Plan"). F2 · price: The price reported in column 4 is the average stock price. F3 · ownership.nature: Sumitovant Biopharma Ltd. ("Sumitovant") directly owns 47,348,604 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document
April 09, 2020 Filed Apr 13, 2020 18:25 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	PurchaseCommon Stock	70,000	$9.37	$655,669.00	Disclosure SEC source: 0000899243-20-010666 · doc4.xml · nonDerivative · entry 1 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 47,278,604 F1 · shares: This acquisition of a total of 70,000 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020. F2 · price: The price reported in column 4 is the average stock price. F3 · ownership.nature: Sumitovant Biopharma Ltd. ("Sumitovant") directly owns 47,278,604 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document
April 08, 2020 Filed Apr 9, 2020 15:20 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	PurchaseCommon Stock	70,000	$8.53	$596,939.00	Disclosure SEC source: 0000899243-20-010563 · doc4.xml · nonDerivative · entry 2 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 47,208,604 F4 · shares: This acquisition of a total of 70,000 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan. F2 · price: The price reported in column 4 is the average stock price. F5 · ownership.nature: Sumitovant directly owns 47,208,604 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document
April 07, 2020 Filed Apr 9, 2020 15:20 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	PurchaseCommon Stock	70,000	$8.21	$574,364.00	Disclosure SEC source: 0000899243-20-010563 · doc4.xml · nonDerivative · entry 1 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 47,138,604 F1 · shares: This acquisition of a total of 70,000 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020 (the "10b5-1 Trading Plan"). F2 · price: The price reported in column 4 is the average stock price. F3 · ownership.nature: Sumitovant Biopharma Ltd. ("Sumitovant") directly owns 47,138,604 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document
April 06, 2020 Filed Apr 7, 2020 17:56 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	PurchaseCommon Stock	70,000	$8.44	$590,520.00	Disclosure SEC source: 0000899243-20-010382 · doc4.xml · nonDerivative · entry 2 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 47,068,604 F4 · shares: This acquisition of a total of 70,000 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan. F2 · price: The price reported in column 4 is the average stock price. F5 · ownership.nature: Sumitovant directly owns 47,068,604 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document
April 03, 2020 Filed Apr 7, 2020 17:56 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	PurchaseCommon Stock	70,000	$7.93	$554,925.00	Disclosure SEC source: 0000899243-20-010382 · doc4.xml · nonDerivative · entry 1 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 46,998,604 F1 · shares: This acquisition of a total of 70,000 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020 (the "10b5-1 Trading Plan"). F2 · price: The price reported in column 4 is the average stock price. F3 · ownership.nature: Sumitovant Biopharma Ltd. ("Sumitovant") directly owns 46,998,604 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document
April 02, 2020 Filed Apr 3, 2020 19:04 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	PurchaseCommon Stock	70,000	$7.73	$541,086.00	Disclosure SEC source: 0000899243-20-010095 · doc4.xml · nonDerivative · entry 2 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 46,928,604 F4 · shares: This acquisition of a total of 70,000 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan. F2 · price: The price reported in column 4 is the average stock price. F5 · ownership.nature: Sumitovant directly owns 46,928,604 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document
April 01, 2020 Filed Apr 3, 2020 19:04 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	PurchaseCommon Stock	70,000	$7.46	$522,298.00	Disclosure SEC source: 0000899243-20-010095 · doc4.xml · nonDerivative · entry 1 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 46,858,604 F1 · shares: This acquisition of a total of 70,000 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020 (the "10b5-1 Trading Plan"). F2 · price: The price reported in column 4 is the average stock price. F3 · ownership.nature: Sumitovant Biopharma Ltd. ("Sumitovant") directly owns 46,858,604 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document
March 31, 2020 Filed Apr 1, 2020 14:55 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	PurchaseCommon Stock	70,000	$7.97	$557,984.00	Disclosure SEC source: 0000899243-20-009776 · doc4.xml · nonDerivative · entry 2 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 46,788,604 F4 · shares: This acquisition of a total of 70,000 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan. F2 · price: The price reported in column 4 is the average stock price. F5 · ownership.nature: Sumitovant directly owns 46,788,604 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document
March 30, 2020 Filed Apr 1, 2020 14:55 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	PurchaseCommon Stock	70,000	$7.65	$535,766.00	Disclosure SEC source: 0000899243-20-009776 · doc4.xml · nonDerivative · entry 1 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 46,718,604 F1 · shares: This acquisition of a total of 70,000 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020 (the "10b5-1 Trading Plan"). F2 · price: The price reported in column 4 is the average stock price. F3 · ownership.nature: Sumitovant Biopharma Ltd. ("Sumitovant") directly owns 46,718,604 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document
March 27, 2020 Filed Mar 30, 2020 15:34 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	PurchaseCommon Stock	70,000	$7.98	$558,250.00	Disclosure SEC source: 0000899243-20-009633 · doc4.xml · nonDerivative · entry 2 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 46,648,604 F4 · shares: This acquisition of a total of 70,000 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan. F2 · price: The price reported in column 4 is the average stock price. F5 · ownership.nature: Sumitovant directly owns 46,648,604 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document
March 26, 2020 Filed Mar 30, 2020 15:34 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	PurchaseCommon Stock	70,000	$7.94	$555,807.00	Disclosure SEC source: 0000899243-20-009633 · doc4.xml · nonDerivative · entry 1 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 46,578,604 F1 · shares: This acquisition of a total of 70,000 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020 (the "10b5-1 Trading Plan"). F2 · price: The price reported in column 4 is the average stock price. F3 · ownership.nature: Sumitovant Biopharma Ltd. ("Sumitovant") directly owns 46,578,604 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document
March 25, 2020 Filed Mar 26, 2020 15:39 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	PurchaseCommon Stock	108,100	$7.60	$821,895.11	Disclosure SEC source: 0000899243-20-009469 · doc4.xml · nonDerivative · entry 2 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 46,508,604 F4 · shares: This acquisition of a total of 108,100 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan. F2 · price: The price reported in column 4 is the average stock price. F5 · ownership.nature: Sumitovant directly owns 46,508,604 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document
March 24, 2020 Filed Mar 26, 2020 15:39 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	PurchaseCommon Stock	211,200	$7.67	$1,620,558.72	Disclosure SEC source: 0000899243-20-009469 · doc4.xml · nonDerivative · entry 1 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 46,400,504 F1 · shares: This acquisition of a total of 211,200 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020 (the "10b5-1 Trading Plan"). F2 · price: The price reported in column 4 is the average stock price. F3 · ownership.nature: Sumitovant Biopharma Ltd. ("Sumitovant") directly owns 46,400,504 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document
March 23, 2020 Filed Mar 24, 2020 19:15 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	PurchaseCommon Stock	211,200	$7.68	$1,621,931.52	Disclosure SEC source: 0000899243-20-009332 · doc4.xml · nonDerivative · entry 2 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 46,189,304 F4 · shares: This acquisition of a total of 211,200 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan. F2 · price: The price reported in column 4 is the average stock price. F5 · ownership.nature: Sumitovant directly owns 46,189,304 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document
March 20, 2020 Filed Mar 24, 2020 19:15 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	PurchaseCommon Stock	193,900	$7.60	$1,472,709.28	Disclosure SEC source: 0000899243-20-009332 · doc4.xml · nonDerivative · entry 1 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 45,978,104 F1 · shares: This acquisition of a total of 193,900 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020 (the "10b5-1 Trading Plan"). F2 · price: The price reported in column 4 is the average stock price. F3 · ownership.nature: Sumitovant Biopharma Ltd. ("Sumitovant") directly owns 45,978,104 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document
March 19, 2020 Filed Mar 20, 2020 18:10 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	PurchaseCommon Stock	193,900	$7.68	$1,488,958.10	Disclosure SEC source: 0000899243-20-009088 · doc4.xml · nonDerivative · entry 2 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 45,784,204 F1 · shares: This acquisition of a total of 193,900 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020. F2 · price: The price reported in column 4 is the average stock price. F4 · ownership.nature: Sumitovant directly owns 45,784,204 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document
March 18, 2020 Filed Mar 20, 2020 18:10 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	PurchaseCommon Stock	193,900	$7.40	$1,434,937.56	Disclosure SEC source: 0000899243-20-009088 · doc4.xml · nonDerivative · entry 1 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 45,590,304 F1 · shares: This acquisition of a total of 193,900 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020. F2 · price: The price reported in column 4 is the average stock price. F3 · ownership.nature: Sumitovant Biopharma Ltd. ("Sumitovant") directly owns 45,590,304 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document
March 17, 2020 Filed Mar 18, 2020 20:21 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	PurchaseCommon Stock	193,900	$7.40	$1,433,948.67	Disclosure SEC source: 0000899243-20-008835 · doc4.xml · nonDerivative · entry 2 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 45,396,404 F1 · shares: This acquisition of a total of 193,900 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020. F2 · price: The price reported in column 4 is the average stock price. F4 · ownership.nature: Sumitovant directly owns 45,396,404 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document
March 16, 2020 Filed Mar 18, 2020 20:21 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	PurchaseCommon Stock	193,900	$7.25	$1,406,007.68	Disclosure SEC source: 0000899243-20-008835 · doc4.xml · nonDerivative · entry 1 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 45,202,504 F1 · shares: This acquisition of a total of 193,900 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020. F2 · price: The price reported in column 4 is the average stock price. F3 · ownership.nature: Sumitovant Biopharma Ltd. ("Sumitovant") directly owns 45,202,504 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document
February 19, 2020 Filed Feb 21, 2020 22:54 UTC	Urovant Sciences Ltd. UROV · Entity 140739	PurchaseCommon Stock	75,212	$13.08	$983,772.96	Disclosure SEC source: 0000950103-20-003118 · dp121731_4-sumitomo.xml · nonDerivative · entry 3 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · See Footnote (1) Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · See Footnote (1) Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 22,963,263 F1 · ownership.nature: Sumitovant Biopharma Ltd. ("Sumitovant") directly owns 22,963,263 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document
February 19, 2020 Filed Feb 21, 2020 22:54 UTC	Urovant Sciences Ltd. UROV · Entity 140739	PurchaseCommon Stock	15,165	$13.08	$198,358.20	Disclosure SEC source: 0000950103-20-003118 · dp121731_4-sumitomo.xml · nonDerivative · entry 2 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · See Footnote (1) Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · See Footnote (1) Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 22,888,051 F1 · ownership.nature: Sumitovant Biopharma Ltd. ("Sumitovant") directly owns 22,963,263 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document
February 19, 2020 Filed Feb 21, 2020 22:54 UTC	Urovant Sciences Ltd. UROV · Entity 140739	PurchaseCommon Stock	12,873	$13.08	$168,378.84	Disclosure SEC source: 0000950103-20-003118 · dp121731_4-sumitomo.xml · nonDerivative · entry 1 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · See Footnote (1) Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · See Footnote (1) Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 22,872,886 F1 · ownership.nature: Sumitovant Biopharma Ltd. ("Sumitovant") directly owns 22,963,263 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.